The development of systemic medicinal products through the nasal route is increasing, as well as new treatments directly targeting the central nervous system (nasal administration avoids the blood-brain barrier).
The nasal route of administration is easily accessible, leading to focused efficacy and outstanding usability.
The purpose of this partnership is to develop a new method of nasal administration.
Marc Haemel, CEO Nemera, said: “There is no limit to Nemera’s ambition to serve patients. We already market devices in over 40 countries for millions of users. We’ll keep investing in new products and in state-of-the-art manufacturing equipment, to help even more patients with high quality devices all over the world.”
This collaboration relies on the expertise of University of Tours (UFRT) in respiratory pre-clinical and clinical research, and Nemera’s experience in development of drug delivery devices.
